Synapsin II Is Involved in the Molecular Pathway of Lithium Treatment in Bipolar Disorder

Bipolar disorder (BD) is a debilitating psychiatric condition with a prevalence of 1–2% in the general population that is characterized by severe episodic shifts in mood ranging from depressive to manic episodes. One of the most common treatments is lithium (Li), with successful response in 30–60% of patients. Synapsin II (SYN2) is a neuronal phosphoprotein that we have previously identified as a possible candidate gene for the etiology of BD and/or response to Li treatment in a genome-wide linkage study focusing on BD patients characterized for excellent response to Li prophylaxis. In the present study we investigated the role of this gene in BD, particularly as it pertains to Li treatment. We investigated the effect of lithium treatment on the expression of SYN2 in lymphoblastoid cell lines from patients characterized as excellent Li-responders, non-responders, as well as non-psychiatric controls. Finally, we sought to determine if Li has a cell-type-specific effect on gene expression in neuronal-derived cell lines. In both in vitro models, we found SYN2 to be modulated by the presence of Li. By focusing on Li-responsive BD we have identified a potential mechanism for Li response in some patients.

[1]  F. Benfenati,et al.  Corrigendum to “The synapsins: Key actors of synapse function and plasticity” [Prog. Neurobiol. 91 (4) (2010) 313–348] , 2011, Progress in neurobiology.

[2]  Guy Rouleau,et al.  Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses. , 2010, The international journal of neuropsychopharmacology.

[3]  F. Benfenati,et al.  The synapsins: Key actors of synapse function and plasticity , 2010, Progress in Neurobiology.

[4]  R. Wightman,et al.  Synapsins Differentially Control Dopamine and Serotonin Release , 2010, The Journal of Neuroscience.

[5]  B. Mittal,et al.  Association of intronic polymorphism rs3773364 A>G in synapsin‐2 gene with idiopathic epilepsy , 2010, Synapse.

[6]  Guoyin Feng,et al.  No association between bipolar disorder and syngr1 or synapsin II polymorphisms in the Han Chinese population , 2009, Psychiatry Research.

[7]  M. McInnis,et al.  MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. , 2009, The international journal of neuropsychopharmacology.

[8]  Guang Chen,et al.  Evidence for Selective microRNAs and Their Effectors as Common Long-Term Targets for the Actions of Mood Stabilizers , 2009, Neuropsychopharmacology.

[9]  M. Alda,et al.  Treatment of bipolar disorder: New perspectives , 2009, Annals of medicine.

[10]  M. Alda,et al.  Lithium response and genetic variation in the CREB family of genes , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[11]  M. Alda,et al.  Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. , 2007, Journal of affective disorders.

[12]  M. Moreau,et al.  Association of synapsin 2 with schizophrenia in families of Northern European ancestry , 2007, Schizophrenia Research.

[13]  F. Goodwin,et al.  Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. , 2006, Bipolar disorders.

[14]  J. Geddes,et al.  Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. , 2005, The American journal of psychiatry.

[15]  Hiroki Shibata,et al.  Association study of polymorphisms in synaptic vesicle-associated genes, SYN2 and CPLX2, with schizophrenia , 2005, Behavioral and Brain Functions.

[16]  A. Serretti,et al.  Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-β −50 T/C SNP , 2005, Neuroscience Letters.

[17]  S. Duan,et al.  Family-based association study of synapsin II and schizophrenia. , 2004, American journal of human genetics.

[18]  J. Cheetham,et al.  Cytoskeletal interactions of synapsin I in non-neuronal cells. , 2004, Biochemical and biophysical research communications.

[19]  M. Alda,et al.  Identification of Lithium-Regulated Genes in Cultured Lymphoblasts of Lithium Responsive Subjects with Bipolar Disorder , 2004, Neuropsychopharmacology.

[20]  J. Smoller,et al.  Family, twin, and adoption studies of bipolar disorder , 2003, American journal of medical genetics. Part C, Seminars in medical genetics.

[21]  Frederick K Goodwin,et al.  Suicide risk in bipolar disorder during treatment with lithium and divalproex. , 2003, JAMA.

[22]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[23]  L. Braiterman,et al.  Synapsin I is expressed in epithelial cells: localization to a unique trans-Golgi compartment. , 2001, Journal of cell science.

[24]  M. Guenther,et al.  Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.

[25]  M. Alda,et al.  Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium , 2001, Molecular Psychiatry.

[26]  P. Genever,et al.  Evidence for targeted vesicular glutamate exocytosis in osteoblasts. , 2001, Bone.

[27]  M. Alda,et al.  Is lithium response related to Gsα levels in transformed lymphoblasts from subjects with bipolar disorder , 2001 .

[28]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[29]  R. Baldessarini,et al.  Does lithium treatment still work? Evidence of stable responses over three decades. , 2000, Archives of general psychiatry.

[30]  W. Volknandt,et al.  A plethora of presynaptic proteins associated with ATP‐storing organelles in cultured astrocytes , 1999, Glia.

[31]  R. Baldessarini,et al.  Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. , 1996, The Journal of clinical psychiatry.

[32]  B. Müller-Oerlinghausen,et al.  Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. , 1996, Pharmacopsychiatry.

[33]  T. Südhof,et al.  Differential distributions of novel synaptotagmins: Comparison to synapsins , 1995, Neuropharmacology.

[34]  S Schoch,et al.  The Human Synapsin II Gene Promoter , 1995, The Journal of Biological Chemistry.

[35]  L. Brodin,et al.  Impairment of synaptic vesicle clustering and of synaptic transmission, and increased seizure propensity, in synapsin I-deficient mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  T. Südhof,et al.  Essential functions of synapsins I and II in synaptic vesicle regulation , 1995, Nature.

[37]  A. Czernik,et al.  Antibodies to an epitope on synapsin I detect a protein associated with the endocytic compartment in non-neuronal cells. , 1994, European journal of cell biology.

[38]  M. Alda,et al.  Lithium response and genetics of affective disorders. , 1994, Journal of affective disorders.

[39]  B. Müller-Oerlinghausen,et al.  Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. , 1992, Journal of affective disorders.

[40]  P. Greengard,et al.  Structure and function of the synapsins. , 1992, The Journal of biological chemistry.

[41]  P. Greengard,et al.  An analysis of synapsin II, a neuronal phosphoprotein, in postmortem brain tissue from alcoholic and neuropsychiatrically ill adults and medically ill children and young adults. , 1990, Archives of general psychiatry.

[42]  P. Greengard,et al.  Cholinergic regulation of protein III phosphorylation in bovine adrenal chromaffin cells , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  P. Greengard,et al.  Cholinergic regulation of protein phosphorylation in bovine adrenal chromaffin cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Greengard,et al.  Similarities between protein IIIa and protein IIIb, two prominent synaptic vesicle-associated phosphoproteins , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[45]  M. Schou.  [Preventive lithium treatment in manic-depressive disease: experiences and progress in recent years]. , 1983, Der Nervenarzt.

[46]  S. Rapoport,et al.  Decrease in the AP-2 DNA-binding activity and in the protein expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated with lithium for 6 weeks. , 2005, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[47]  J. Kleinman,et al.  Reduction of synapsin in the hippocampus of patients with bipolar disorder and schizophrenia , 2002, Molecular Psychiatry.

[48]  M. Alda,et al.  Is lithium response related to G(s)alpha levels in transformed lymphoblasts from subjects with bipolar disorder? , 2001, Journal of affective disorders.

[49]  P. Greengard,et al.  The synapsins. , 1990, Annual review of cell biology.